Conclusion the developed synthetic medium and purification procedure were feasible and provided an experimental basis for the preparation of tetravalent meningococcus polysaccharide vaccine.
A tetravalent meningococcal meningitis vaccine (licensed in the United States) and a heptavalent vaccine protecting against meningitis A and C (to be licensed in 2007);